High-density array comparative genomic hybridization detects novel copy number alterations in gastric adenocarcinoma

Anticancer Research

Volumn 34, Issue 11, 2014, Pages 6405-6415

  Seabra, Aline Damasceno ^a   Araújo, Taíssa Maíra Thomaz ^a   Mello, Fernando Augusto Rodrigues ^a   Alcântara, Diego Di Felipe Ávila ^a   De Barros, Amanda Paiva ^a   De Assumpҫão, Paulo Pimentel ^a   Montenegro, Raquel Carvalho ^a   Guimarães, Adriana Costa ^a   Demachki, Samia ^a   Burbano, Rommel Mario Rodríguez ^a   Khayat, André Salim ^a  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

aCGH; Carcinogenesis; Gastric adenocarcinoma; Intestinal type

Indexed keywords

ADAM3A GENE; ADAM6 GENE; ADULT; AGED; ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; ARTICLE; ASXL1 GENE; B4GALT5 GENE; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CDH8 GENE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CYP24A1 GENE; ERBB4 GENE; FEMALE; FHIT GENE; GBE1 GENE; GENE; GPC5 GENE; HETEROZYGOSITY LOSS; HUMAN; KIAA0125 GENE; LRP1B GENE; LUZP2 GENE; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; NRG3 GENE; PRPF6 GENE; PTPN1 GENE; RGS19 GENE; ROBO2 GENE; RTEL1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC2A4RG GENE; SOX18 GENE; SOX6 GENE; STOMACH ADENOCARCINOMA; TNFRSF6B GENE; TP53TG3 GENE; TP53TG3B GENE; TPD52L2 GENE; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; ZBTB46 GENE; ZGPAT GENE; ZNF267 GENE; ADENOCARCINOMA; CHROMOSOMAL INSTABILITY; GENETICS; HUMAN CHROMOSOME; INTESTINE TUMOR; PATHOLOGY; PROCEDURES; PROGNOSIS; STOMACH TUMOR; VERY ELDERLY;

DNA; MICROSATELLITE DNA; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMAL INSTABILITY; CHROMOSOMES, HUMAN; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; HUMANS; INTESTINAL NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84916233772     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Konturek PC, Konturek SJ and Brzozowski T: Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol 60: 3-21, 2009.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
3. Globocan. Cancer Incidence and Mortality Worldwide in 2008. Online and available from: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#BOTH.
4. Instituto Nacional de Câncer - INCA. Estimativa 2014: incidência de câncer no Brasil. Rio de Janeiro, INCA, p. 124, 2014.
5. Resende AL, Mattos IE and Koifman S: Gastric cancer mortality in the state of Pará, Brazil, 1980-1997. Arq Gastroenterol 43: 247-51, 2006.
6. Laurén P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
7. Bosoteanu C, Bosoteanu M and Aschie M: Differential diagnosis issues in a case of gastric carcinoma associated with leukemoid reaction. Rom J Morphol Embryol 50: 701-705, 2009.
8. Lemes LAO, Neunschwander LC, Matta LAC, Osório-Filho J, Soares PCM, Cabral MMDA, Nogueira AMMF and Rodrigues MAG: Carcinoma gástrico: análise sistemática de 289 gastrectomias consecutivas em Belo Horizonte (MG). J Bras Patol Med Lab 39: 57-65, 2003.
9. Marigo C, Okuyama MH and Santo GC: Hystological types and mortality for gastric cancer in São Paulo, Brazil. Cad Saúde Pública 13: 93-7, 1997.
10. Schildberg CW, Abba M, Merkel S, Agaimy A, Dimmler A, Schlabrakowski A, Croner R, Leupold JH, Hohenberger W and Allgayer H: Gastric cancer patients less than 50 years of age exhibit significant down-regulation of E-cadherin and CDX2 compared to older reference populations. Adv Med Sci 59: 142-6, 2014.
11. Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y and Ansaloni L: Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 40: 12-26, 2014.
12. Goéré D, Gras-Chaput N, Aupérin A, Flament C, Mariette C, Glehen O, Zitvogel L and Elias D: Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer 14: 148, 2014.
13. Milne AN and Offerhaus GJ: Early-onset gastric cancer: Learning lessons from the young. World J Gastrointest Oncol 2: 59-64, 2010.
14. Shankar G, Rossi MR, McQuaid DE, Conroy JM, Gaile DG, Cowell JK, Nowak NJ and Liang P: aCGHViewer: a generic visualization tool for aCGH data. Cancer Inform 2: 36-43, 2006.
15. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, Kodama T and Aburatani H: Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 61: 889-895, 2001.
16. El-Rifai W, Frierson HF Jr, Harper JC, Powell SM and Knuutila S: Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer 93: 832-838, 2001.
17. Lee S, Baek M, Yang H, Bang YJ, Kim WH, Ha JH, Kim DK and Jeoung DI: Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett 184: 197-206, 2002.
18. Ji J, Chen X, Leung SY, Chi JT, Chu KM, Yuen ST, Li R, Chan AS, Li J, Dunphy N and So S: Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene 21: 6549-6556, 2002.
19. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, Kodama T and Aburatani H: Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62: 233-240, 2002.
20. Liu LX, Liu ZH, Jiang HC, Qu X, Zhang WH, Wu LF, Zhu AL, Wang XQ and Wu M; Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array. World J Gastroenterol 8: 580-585, 2002.
21. Meireles SI, Carvalho AF, Hirata R, Montagnini AL, Martins WK, Runza FB, Stolf BS, Termini L, Neto CE, Silva RL, Soares FA, Neves EJ and Reis LF: Differentially expressed genes in gastric tumors identified by cDNA array. Cancer Lett 190: 199-211, 2003.
22. Ayres M, Ayres JR, Ayres DL and Santos AS: BioEstat 5.0: Aplicac¸ões estatísticas nas áreas das ciências biológicas e médicas. Mamirauá, Belém, p. 364, 2007.
23. Ng CC, Koyama K, Okamura S, Kondoh H, Takei Y and Nakamura Y: Isolation and characterization of a novel TP53-inducible gene, TP53TG3. Genes Chromosomes Cancer 26: 329-35, 1999.
24. Blaschke S, Mueller CA, Markovic-Lipkovski J, Puch S, Miosge N, Becker V, Mueller GA and Klein G: Expression of cadherin-8 in renal cell carcinoma and fetal kidney. Int J Cancer 101: 327-34, 2002.
25. Saitoh T and Katoh M: Expression of human SOX18 in normal tissues and tumors. Int J Mol Med 10: 339-44. 2002.
26. Wu M, Michaud EJ and Johnson DK: Cloning, functional study and comparative mapping of Luzp2 to mouse chromosome 7 and human chromosome 11p13-11p14. Mamm Genome 14: 323-334, 2003.
27. Dunn M, Sinha P, Campbell R, Blackburn E, Levinson N, Rampaul R, Bates T, Humphreys S and Gullick WJ: Coexpression of neuregulins 1, 2, 3 and 4 in human breast cancer. J Pathol 203: 672-680, 2004.
28. Ordway JM, Bedell JA, Citek RW, Nunberg A, Garrido A, Kendall R, Stevens JR, Cao D, Doerge RW, Korshunova Y, Holemon H, McPherson JD, Lakey N, Leon J, Martienssen RA and Jeddeloh JA: Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis 27: 2409-2423, 2006.
29. Boulaiz H, Prados J, Melguizo C, Marchal JA, Carrillo E, Peran M, Rodríguez-Serrano F, Martínez-Amat A, Caba O, Hita F, Concha A and Aránega A: Tumour malignancy loss and cell differentiation are associated with induction of GEF gene in human melanoma cells. Br J Dermatol 159: 370-378, 2008.
30. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider A, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M and Murty VV; Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 47: 755-765, 2008.
31. Lee D, Yu M, Lee E, Kim H, Yang Y, Kim K, Pannicia C, Kurie JM and Threadgill DW: Tumor-specific apoptosis caused by deletion of the Erbb3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest 119: 2702-2713, 2009.
32. Narayan G and Murty VV: Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Future Oncol 6: 1643-1652, 2010.
33. Tso PH, Yung LY, Wang Y and Wong YH: RGS19 stimulates cell proliferation by deregulating cell cycle control and enhancing AKT signaling. Cancer Lett 309: 199-208, 2011.
34. Schnabl B, Valletta D, Kirovski G and Hellerbrand C: Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Exp Mol Pathol 91: 695-701, 2011.
35. Wu X, Sandhu S, Nabi Z and Ding H: Generation of a mouse model for studying the role of up-regulated Rtel1 activity in tumorigenesis. Transgenic Res 21: 1109-1115, 2012.
36. Zhou J, Song SD, Li DC, Zhou J, Zhu DM and Zheng SY: Clinical significance of expression and amplification of the DCR3 gene in pancreatic carcinomas. Asian Pac J Cancer Prev 13: 719-724, 2012.
37. Zhang C, Zhang S, Zhang D, Zhang Z, Xu Y and Liu S: A lung cancer gene GPC5 could also be crucial in breast cancer. Mol Genet Metab 103: 104-105, 2011.
38. Song X, Zhou K, Zhao Y, Huai C, Zhao Y, Yu H, Chen Y, Chen G, Chen H, Fan W, Mao Y and Lu D: Fine mapping analysis of a region of 20q13.33 identified five independent susceptibility loci for glioma in a Chinese Han population. Carcinogenesis 33: 1065-1071, 2012.
39. Ni S, Hu J, Duan Y, Shi S, Li R, Wu H, Qu Y and Li Y: Down expression of LRP1B promotes cell migration via RHOA/CDC42 pathway and actin cytoskeleton remodeling in renal cell cancer. Cancer Sci 104: 817-825, 2013.
40. Höbaus J, Hummel DM, Thiem U, Fetahu IS, Aggarwal A, Müllauer L, Heller G, Egger G, Mesteri I, Baumgartner-Parzer S and Kallay E: Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. Int J Cancer 133: 1380-1388, 2013.
41. Flossbach L, Holzmann K, Mattfeldt T, Buck M, Lanz K, Held M, Möller P and Barth TF: High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant. Int J Cancer 132: E116-127, 2013.
42. Guo X, Yang M, Gu H, Zhao J and Zou L: Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma. Cancer Epidemiol 37: 732-736, 2013.
43. Zhou H, Ma H, Wei W, Ji D, Song X, Sun J, Zhang J and Jia L: B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance associated protein 1. Cell Death Dis 4: e654, 2013.
44. Loo LW, Tiirikainen M, Cheng I, Lum-Jones A, Seifried A, Church JM, Gryfe R, Weisenberger DJ, Lindor NM, Gallinger S, Haile RW, Duggan DJ, Thibodeau SN, Casey G and Le Marchand L: Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype-negative colon cancer. Genes Chromosomes Cancer 52: 450-466, 2013.
45. Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfoør K, Holm R, Kristensen GB, Steenbergen RD and Lyng H: Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J Pathol 230: 59-69, 2013.
46. Choi YJ, Yoo NJ and Lee SH: Down-regulation of ROBO2 expression in prostate cancers. Pathol Oncol Res 20: 517-519, 2013.
47. Edsgärd D, Dalgaard MD, Weinhold N, Wesolowska-Andersen A, Rajpert-De Meyts E, Ottesen AM, Juul A, Skakkebæk NE, Skoøt Jensen T, Gupta R, Leffers H and Brunak S: Genome-wide assessment of the association of rare and common copy number variations to testicular germ cell cancer. Front Endocrinol 4: 2, 2013.
48. Kapitanović S, Čačev T2, Lončar B3, Catela Ivković T2, Križanac Š4 and Pavelić K2: Reduced FHIT expression is associated with tumor progression in sporadic colon adenocarcinoma. Exp Mol Pathol 96: 92-97, 2014.
49. Chiu CG, Nakamura Y, Chong KK, Huang SK, Kawas NP, Triche T, Elashoff D, Kiyohara E, Irie RF, Morton DL and Hoon DS: Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60: 873-885, 2014.
50. Xi C, Ren C, Hu A, Lin J, Yao Q, Wang Y, Gao Z, An X and Liu C: Defective expression of protein 4.1N is correlated to tumor progression, aggressive behaviors and hemotherapy resistance in epithelial ovarian cancer. Gynecol Oncol 131: 764-771, 2013.
51. Zhenyu J, Xiaofang S, Xin L, Yu S, Qingqing Z, Xilong L, Li L, Xiang J, Yanfeng G, Yuanming Q and Qiaozhen K: The membrane-cytoskeletal protein 4.1N is involved in the process of cell adhesion, migration and invasion of breast cancer cells. Exp Ther Med 4: 736-740, 2012.
52. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, Tepper RI and Shyjan AW: Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58: 1515-1520, 1998.
53. Tsavaler L, Shapero MH, Morkowski S and Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 61: 3760-3769, 2001.
54. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A, Reus K, Meese E, Bonkhoff H and Flockerzi V: Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem 276: 19461-19468, 2001.
55. 2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 66: 2038-2047, 2006.
56. Oh C, Park S, Lee EK and Yoo YJ: Down-regulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic interventio. Sci Rep 3: 2623, 2013.
57. Cho JH, Noguchi M, Ochiai A and Hirohashi S: Loss of heterozygosity of multiple tumor suppressor genes in human gastric cancers by polymerase chain reaction. Lab Invest 74: 835-841, 1996.
58. Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H and Croce CM: Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Clin Cancer Res 6: 1372-7, 2000.
59. Albertson DG: Gene amplification in cancer. Trends Genet 22: 447-455, 2006.
60. Panani AD: Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 266: 99-115, 2008.
61. Blandino G, Fazi F, Donzelli S, Kedmi M, Sas-Chen A, Muti P, Strano S6 and Yarden Y: Tumor suppressor microRNAs: A novel non-coding alliance against cancer. FEBS Lett 2014.
62. Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A and Merlano M: Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol 37: 1219-1228, 2010.
63. Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P and Ji M: Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 13: 4714-4726, 2012.
64. Silva SD, Alaoui-Jamali MA, Hier M, Soares FA, Graner E and Kowalski LP: Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread. Clin Exp Metastasis 31: 307-316, 2014.
65. Zhang M, Yang Q, Zhang L, Zhou S, Ye W, Yao Q, Li Z, Huang C, Wen Q and Wang J: miR-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ERBB4. J Exp Clin Cancer Res 33: 10, 2014.
66. Gallo RM, Bryant IN, Mill CP, Kaverman S and Riese DJ 2nd. Multiple functional motifs are required for the tumor suppressor activity of a constitutively active ERBB4 mutant. J Cancer Res Ther Oncol 1: 10, 2013.
67. Fujiwara S, Ibusuki M, Yamamoto S, Yamamoto Y and Iwase H: Association of ERBB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. Breast Cancer 21: 472-81, 2012.
68. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E and Nesland JM: EGFR family expression in breast carcinomas. c-ERBB-2 and c-ERBB-4 receptors have different effects on survival. J Pathol 196: 17-25, 2002.
69. Witton CJ, Reeves JR, Going JJ, Cooke TG and Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290-297, 2003.
70. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF and Bundred NJ: Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 11: 2163-2168, 2005.
71. Jackson-Fisher AJ, Bellinger G, Shum E, Duong JK, Perkins AS, Gassmann M, Muller W, Kent Lloyd KC and Stern DF: Formation of Neu/ERBB2-induced mammary tumors is unaffected by loss of ERBB4. Oncogene 25: 5664-5672, 2006.
72. Qin YR, Tang H, Xie F, Liu H, Zhu Y, Ai J, Chen L, Li Y, Kwong DL, Fu L and Guan XY: Characterization of tumorsuppressive function of SOX6 in human esophageal squamous cell carcinoma. Clin Cancer Res 17: 46-55, 2011.
73. Ueda R, Ohkusu-Tsukada K, Fusaki N, Soeda A, Kawase T, Kawakami Y and Toda M: Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer 126: 919-929, 2010.
74. Delahanty RJ, Beeghly-Fadiel A, Xiang YB, Long J, Cai Q, Wen W, Xu WH, Cai H, He J, Gao YT, Zheng W and Shu XO: Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai endometrial cancer genetics study. Am J Epidemiol 174: 1115-11126, 2011.
75. Brookman-Amissah N, Duchesnes C, Williamson MP, Wang Q, Ahmed A, Feneley MR, Mackay A, Freeman A, Fenwick K, Iravani M, Weber B, Ashworth A and Masters JR: Genomewide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH. Prostate Cancer Prostatic Dis 8: 335-343, 2005.
76. Nicolet C, Guérin E, Neuville A, Kerckaert JP, Wicker N, Bergmann E, Brigand C, Kedinger M, Gaub MP and Guenot D: Evidence for various 20q status using allelotyping, CGH arrays, and quantitative PCR in distal CIN colon cancers. Cancer Lett 282: 195-204, 2009.
77. Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B and Meijer GA: High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 455: 213-223, 2009.
78. Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G and Bondy M: Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res 4: 1609-1616, 2011.
79. Pryor JG, Brown-Kipphut BA, Iqbal A and Scott GA: Microarray comparative genomic hybridization detection of copy number changes in desmoplastic melanoma and malignant peripheral nerve sheath tumor. Am J Dermatopathol 33: 780-785, 2011.
80. Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K, Gudjonsson S, Liedberg F, Patschan O, Ma˚nsson W, FernöM and Höglund M: Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One 7: e38863, 2012.
81. Capurso G, Festa S, Valente R, Piciucchi M, Panzuto F, Jensen RT and Delle Fave G: Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol 49: R37-50, 2012.
82. van den Tillaart SA, Corver WE, Ruano Neto D, ter Haar NT, Goeman JJ, Trimbos JB, Fleuren GJ and Oosting J: Loss of heterozygosity and copy number alterations in flow-sorted bulky cervical cancer. PLoS One 8: e67414, 2013.
83. Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V and Domany E: Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One 6: e14632, 2011.
84. Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M and Kikuchi M: Amplification and expression of a decoy receptor for FAS ligand (DCR3) in virus (EBV or HTLVI) associated lymphomas. Cancer Lett 160: 89-97, 2000.
85. Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J and Hayashi Y: Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol 109: 294-298, 2005.
86. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T and Nakajima Y: The prognostic significance of overexpression of the decoy receptor for FAS ligand (DCR3) in patients with gastric carcinomas. Gastric Cancer 5: 61-68, 2002.
87. Wu Y, Guo E, Yu J, Xie Q and Chen J: High DCR3 expression predicts stage pN2 in gastric cancer. Hepatogastroenterology 54: 2172-2176, 2008.
88. Yang D, Fan X, Yin P, Wen Q, Yan F, Yuan S, Liu B, Zhuang G and Liu Z: Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer. BMC Immunol 13: 28, 2012.
89. Kuller LH: Age-adjusted death rates: A hazard to epidemiology? Ann Epidemiol 9: 91-92, 1999.
90. Zheng CH, Lu J, Huang CM, Li P, Xie JW, Wang JB and Lin JX: Clinicopathologic features and prognosis of gastric cancer in young patients. Zhonghua Wei Chang Wai Ke Za Zhi 16: 40-43, 2013.
91. Carvalho R, Milne AN, van Rees BP, Caspers E, Cirnes L, Figueiredo C, Offerhaus GJ and Weterman MA: Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. J Pathol 204: 75-83, 2004.
92. Buffart TE, Carvalho B, Hopmans E, Brehm V, Kranenbarg EK, Schaaij-Visser TB, Eijk PP, van Grieken NC, Ylstra B, van de Velde CJ and Meijer GA: Gastric cancers in young and elderly patients show different genomic profiles. J Pathol 211: 45-51, 2007.
93. Varis A, van Rees B, Weterman M, Ristimäki A, Offerhaus J and Knuutila S: DNA copy number changes in young gastric cancer patients with special reference to chromosome 19. Br J Cancer 88: 1914-1919, 2003.
94. Genecards. The Human Gene Compendium. Online and Available from: URL: http://www.genecards.org/.
95. Gkika D and Prevarskaya N: TRP channels in prostate cancer: the good, the bad and the ugly? Asian J Androl 13: 673-676, 2011.
96. Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, Gkika D, Pourtier A, Bidaux G, Slomianny C, Delcourt P, Rassendren F, Bergerat JP, Ceraline J, Cabon F, Humez S and Prevarskaya N: Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res 70: 1225-1235, 2010.
97. Larramendy ML, el-Rifai W, Kokkola A, Puolakkainen P, Monni O, Salovaara R, Aarnio M and Knuutila S: Comparative genomic hybridization reveals differences in DNA copy number changes between sporadic gastriccarcinomas and gastric carcinomas from patients with hereditary nonpolyposis colorectal cancer. Cancer Genet Cytogenet 106: 62-65, 1998.
98. Zhu YQ, Zhu ZG, Liu BY, Chen XH, Yin HR and Wang XH: Chromosomal alterations analyzed by comparative genomic hybridization in primary gastric carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi 10: 160-164, 2007.
99. Ciechanover A and Schwartz AL: The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim Biophys Acta 1695: 3-17, 2004.
100. Hoeller D and Dikic I: Targeting the ubiquitin system in cancer therapy. Nature 458: 438-444, 2009.
101. Ishibashi Y, Takada K, Joh K, Ohkawa K, Aoki T and Matsuda M: Ubiquitin immunoreactivity in human malignant tumours. Br J Cancer 63: 320-322, 1991.
102. Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, Okada F, Sato S, Shimbara N and Ichihara A: Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 51: 6677-6685, 1991.
103. Finch JS, St John T, Krieg P, Bonham K, Smith HT, Fried VA and Bowden GT: Overexpression of three ubiquitin genes in mouse epidermal tumors is associated with enhanced cellular proliferation and stress. Cell Growth Differ 3: 269-278, 1992.
104. Ishibashi Y, Hanyu N, Suzuki Y, Yanai S, Tashiro K, Usuba T, Iwabuchi S, Takahashi T, Takada K, Ohkawa K, Urashima M and Yanaga K: Quantitative analysis of free ubiquitin and multiubiquitin chain in colorectal cancer. Cancer Lett 211: 111-117, 2004.
105. Morelva TdeM and Antonio LB: Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. Virchows Arch 455: 235-243, 2009.
106. Osada T, Sakamoto M, Nishibori H, Iwaya K, Matsuno Y, Muto T and Hirohashi S: Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. J Hepatol 26: 1266-1273, 1997.
107. Schulz WA, Ingenwerth M, Djuidje CE, Hader C, Rahnenführer J and Engers R: Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer 10: 505, 2010.
108. Wozny C, Breustedt J, Wolk F, Varoqueaux F, Boretius S, Zivkovic AR, Neeb A, Frahm J, Schmitz D, Brose N and Ivanovic A: The function of glutamatergic synapses is not perturbed by severe knockdown of 4.1N and 4.1G expression. J Cell Sci 122: 735-744, 2009.
109. Shull AY, Clendenning ML, Ghoshal-Gupta S, Farrell CL, Vangapandu HV, Dudas L, Wilkerson BJ and Buckhaults PJ: Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. PLoS One 8: e58731, 2013.